NASDAQ OMX

AbCellera Announces Expanded Research Collaboration with Teva

Dela

Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform

VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd.  Under the agreement, which builds on a successful first partnership completed in 2016, AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform for the discovery of antibodies that modulate the function of an undisclosed membrane protein target elected by Teva. 

Carl Hansen, founding CEO of AbCellera, commented: "We are excited to expand our relationship with the innovative team at Teva. This follow-on project marks an important step in establishing AbCellera's platform as an enabling technology for difficult target classes that have proven intractable by conventional antibody discovery methods."

"We are pleased to extend our work with AbCellera utilizing this company's novel biologics technology," said Steffen Nock, SVP & Global Head of Biologics at Teva. "This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva's capabilities in novel biologics discovery."

Under the terms of the agreement, AbCellera will receive an upfront payment and research support, as well as milestone and royalty payments based on Teva's development and commercialization of antibodies generated under this collaboration. Further terms of the agreement are not disclosed.

About AbCellera Biologics, Inc. 

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera's lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates from any species, including humans.

Contact
Kevin Heyries, PhD
Telephone: 604.827.4151
Email: media@abcellera.com
Web: www.abcellera.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

ShoCard Meets EU's GDPR 'Privacy by Design' Standards through its Identity Management Solutions22.1.2018 16:12Pressmeddelande

Blockchain-based identity management platform addresses provisions of EU data legislation CUPERTINO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ShoCard, a leading blockchain-based identity management system (IMS), today announces its technology meets the European Union's (EU) new regulatory framework for data, known as the General Data Protection Regulation (GDPR), "Privacy by Design" standards. The IMS removes the necessity for authentication data to be stored on organization databases. Instead, it is stored completely on the user's mobile device, secured with their private key and shared via the blockchain. Affected EU-based companies, as well as U.S.-based and other foreign-based companies, processing or holding the personal data of persons residing in the EU, no matter where they are located or where its data is processed within the region, are expected to have GDPR compliant solutions in place ahead of the legislation's enforcement date of May 25, 2018. With user privacy at the cor

Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation22.1.2018 15:30Pressmeddelande

NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) today announced that Cielo S.A. (BVMF:CIEL3) (OTC:CIOXY) (Nasdaq:CIOXY), a tech retail services company, leading the electronic payments sector in Latin America as one of the top 10 Brazilian corporations in terms of market value, is the latest company to join the Nasdaq International Designation. Through its membership, Cielo will have access to Nasdaq's investor relations services and unparalleled visibility assets to increase awareness with investors for their U.S.-traded Level 1 ADRs. The Nasdaq International Designation is available to non-U.S. companies that have Level 1 ADRs or shares that trade on the over-the-counter market. Cielo joins additional South American Member companies Minerva Foods S.A. (BVMF: BEEF3/OTC - Nasdaq Intl: MRVSY) and Marfrig Global Foods S.A. (BVMF: MRFG3/OTC - Nasdaq Intl: MRRTY). "We have seen strong sign of return to growth in South America and many companies are looking to tap int

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 15:10Pressmeddelande

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

FDA Grants Diazyme 510(k) Clearance to Market Its New EZ Vitamin D Assay for Clinical Chemistry Analyzers22.1.2018 15:00Pressmeddelande

SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its EZ Vitamin D assay for Clinical Chemistry Analyzers. Diazyme's two reagent EZ Vitamin D assay provides the only fully automated two reagent Vitamin D test for use on validated clinical chemistry analyzers. "Diazyme's EZ Vitamin D assay is a universal fully automated Vitamin D test that is specifically designed for use on clinical chemistry analyzers. This liquid stable, ready-to-use two reagent system measures total 25-hydroxy Vitamin D (25-OH Vitamin D2 + 25-OH Vitamin D3) levels. This assay enables clinical laboratories of almost any size to run Vitamin D test in house without the need for expensive specialized instrumentation. With no sample pre-treatment or pre-dilution steps required, this high-throughput liquid stable assay provides precise test results, is user friendly, cost effective and has excellen

Fura Completes Acquisition of Colombian Emerald Mine, Coscuez22.1.2018 13:00Pressmeddelande

TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Fura Gems Inc. (TSXV:FURA) is pleased to announce that it has completed its acquisition of 76% of the issued and outstanding shares of Esmeracol S.A. ("Esmeracol"), which owns a 100% interest in mining licence no. 122 - 95M (the "Coscuez Licence"). Dev Shetty, President & CEO of Fura, commented: "Fura has achieved one more important milestone by adding the iconic Colombian emerald mine, Coscuez, to its portfolio. With this acquisition, Fura now has two important silos in its portfolio, Colombian emeralds and Mozambican rubies. Fura will now work towards modernisation of the Coscuez emerald mine and deployment of the best health and safety standards for its employees while keeping the environmental impact minimal. Fura will also closely work with the local community and relevant authorities to promote the social-economic development in the region. We would like to thank our local partner and also the entire team on the ground in the Colombia fo

Agency for the Cooperation of Energy Regulators (ACER) continues to use Nasdaq's SMARTS for Pan-European Market Monitoring of EU Wholesale Energy Markets22.1.2018 12:30Pressmeddelande

NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Agency for the Cooperation of Energy Regulators (ACER) has officially extended its contract with Nasdaq (Nasdaq:NDAQ) to continue to leverage Nasdaq's SMARTS Market Surveillance technology to detect insider trading and market manipulation across the European Union's wholesale energy markets by digesting and analyzing massive volumes of data from hundreds of power producers, exchanges, operators, and brokers across 28 member states. The new agreement contract extension will continue to allow national regulatory authorities to share data, technology, and expertise, with the aim of creating a cooperative regulatory infrastructure. Under the contract, SMARTS technology will continue being leveraged to monitor the European wholesale gas and electricity markets, covering both spot trading and derivative markets across Europe in accordance with the obligations under the REMIT legislation. Further, the surveillance technology will support ACER's

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum